NCT07543510 2026-04-22
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Phase NA Not yet recruiting
Clinical Trials
1,714 trialsNCT07543783 2026-04-22
Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by TACE-HAIC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07544121 2026-04-22
Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis
Nanfang Hospital, Southern Medical University
Phase NA Not yet recruiting
NCT05103904 2026-04-21
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Emory University
Phase 2 Terminated
NCT06860490 2026-04-21
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Fudan University
Phase 2 Recruiting
NCT07487402 2026-04-21
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
Zhejiang University
Phase EARLY_PHASE1 Not yet recruiting
NCT01899261 2026-04-20
Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Montefiore Medical Center
Phase NA Completed
NCT03655002 2026-04-20
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03942328 2026-04-20
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
Phase 1/2 Recruiting
NCT04605731 2026-04-20
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06233981 2026-04-17
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT07535840 2026-04-17
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
Tongji Hospital
Phase NA Not yet recruiting
NCT07537777 2026-04-17
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT07537946 2026-04-17
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
Tongji Hospital
Phase 3 Not yet recruiting
NCT07537959 2026-04-17
Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
Tongji Hospital
Phase NA Not yet recruiting
NCT07537972 2026-04-17
Denosumab Strategy for Liver Cancer With Bone Metastases
Tongji Hospital
Phase 2 Not yet recruiting
NCT02626312 2026-04-16
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT07476651 2026-04-16
LASER
Seoul National University Hospital
Phase NA Recruiting
NCT04785534 2026-04-15
Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05394259 2026-04-15
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06968195 2026-04-15
Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma
Roswell Park Cancer Institute
Phase 1 Suspended
NCT06086002 2026-04-13
Clinical Feasibility of Microwave Ablation Using Two Channel Microwave Generator and Two Antennas for Small Hepatocellular Carcinoma
Seoul National University Hospital
Phase NA Completed
NCT06426992 2026-04-13
Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies
Seoul National University Hospital
Phase NA Recruiting
NCT06938945 2026-04-13
Electronic Symptom Monitoring of Patient-Reported Outcomes Among Patients With Hepatocellular Carcinoma During Immunotherapy (PRIME-HCC): Protocol for a Randomised Controlled Trial
Peking University
Phase NA Recruiting
NCT07192172 2026-04-13
ERFA
Seoul National University Hospital
Phase NA Completed
NCT07522411 2026-04-13
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Tongji Hospital
Phase 1/2 Not yet recruiting
NCT04180072 2026-04-09
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
National Health Research Institutes, Taiwan
Phase NA Active not recruiting
NCT07518706 2026-04-09
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07166406 2026-04-08
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
Phase 3 Recruiting
NCT07514429 2026-04-07
RELEVANT-HCC
Asan Medical Center
Phase 2 Not yet recruiting
NCT07514455 2026-04-07
RECOMEND
Asan Medical Center
Phase 2 Not yet recruiting
NCT07515469 2026-04-07
A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07511504 2026-04-06
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT03186898 2026-04-03
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT03680508 2026-04-02
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
University of Hawaii
Phase 2 Active not recruiting
NCT06553885 2026-04-01
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07062055 2026-04-01
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT02435953 2026-03-31
TORCH
Sun Yat-sen University
Phase 3 Completed
NCT03727633 2026-03-31
LIDA-BII
University Hospital, Montpellier
Phase 2 Terminated
NCT07075120 2026-03-31
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Not yet recruiting
NCT07312292 2026-03-30
RADIANT
UMC Utrecht
Phase 2 Recruiting
NCT05622136 2026-03-27
STRAT-aHCC
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT06311396 2026-03-27
Development of a Neuronal Microscope
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase NA Completed
NCT06902246 2026-03-27
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Recruiting
NCT07331883 2026-03-27
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Ruijin Hospital
Phase 2 Recruiting
NCT07495215 2026-03-27
A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
Sir Run Run Shaw Hospital
Phase 1/2 Recruiting
NCT07495579 2026-03-27
REVIVE
Asan Medical Center
Phase 2 Not yet recruiting
NCT07365839 2026-03-25
CLeAR
Virginia Commonwealth University
Phase 1 Not yet recruiting
NCT07493070 2026-03-25
Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca
Fujian Medical University Union Hospital
Phase NA Active not recruiting